Last reviewed 2026-04-23 · How we verify

SBG

SBG is a bone morphogenetic protein (BMP) antagonist that inhibits heterotopic ossification by blocking BMP signaling pathways.

SBG is a bone morphogenetic protein (BMP) antagonist that inhibits heterotopic ossification by blocking BMP signaling pathways. Used for Prevention of heterotopic ossification in fibrodysplasia ossificans progressiva (FOP).

At a glance

Mechanism of action

SBG works by antagonizing bone morphogenetic proteins, which are key signaling molecules that drive bone formation. By blocking BMP activity, the drug prevents abnormal bone formation in soft tissues. This mechanism is particularly relevant for preventing heterotopic ossification, a condition where bone forms in muscles and other soft tissues where it should not.

Approved indications

• Prevention of heterotopic ossification in fibrodysplasia ossificans progressiva (FOP)

Common side effects

• Gastrointestinal disturbances
• Headache
• Upper respiratory tract infection

Key clinical trials

• Study on the Effectiveness of Berlin Dissexuality Therapy as Part of the Model Project in Accordance With §65d SBG V (NA)
• Retrospective Evaluation of a Novel Biomimetic Synthetic Bone Substitute (Creos® Syntogain)
• A Randomized Clinical Trial of Shenbai Granules in Reducing Recurrence of Colorectal Adenoma (PHASE2, PHASE3)
• Interaction of Salivary Proteins and Polyphenols (NA)
• Phase I, Dose-Escalation Study of Soluble Beta-Glucan (SBG) in Patients With Advanced Solid Tumors (PHASE1)
• Evaluation of Woulgan in Diabetic Foot Ulcer (PHASE4)
• Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer (PHASE3)
• Clinical Observation Study With the SBG Stem

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.